{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:03Z","timestamp":1787026983265,"version":"build-2736575974"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>De novo<\/jats:italic>\n                      neuroendocrine prostate cancer (NEPC) is a rare subtype of prostate cancer (PCa) and few markers are available for screening and monitoring. Potential circulating or fluid markers might facilitate early diagnosis thus improving prognosis of NEPC, especially for\n                      <jats:italic>de novo<\/jats:italic>\n                      NEPC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A man of 71-year was presented with elevated level of serum carcinoembryonic antigen (CEA) (1296.5 ng\/ml) and normal PSA (0.47ng\/ml). Gastrointestinal endoscopy showed no signs of gastric or colorectal cancer. Fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET-CT) and prostate-specific membrane antigen PET-CT (PSMA PET-CT) indicated prostate cancer with metastases including pelvic lymph nodes, bone as well as lung metastases. Biopsy of prostate revealed mixed carcinoma including small cell neuroendocrine carcinoma (SCNEC) and adenocarcinoma (Gleason score of 4 + 5). Immunohistochemistry (IHC) staining and next generation sequencing demonstrated a strong expression of chromogranin A (CgA), synaptophysin (SYN) and CEA, and a germline mutation in BRCA2, respectively. After a prostatic massage, an increased level of CEA (137 ng\/ml vs 5 ng\/ml) was detected in urine. Olaparib, a Poly ADP-ribose polymerase inhibitor (PARPi), combined with androgen deprivation therapy (ADT) were administrated. FDG PET-CT indicated tumor regression in both quantity and size three months later, and CEA levels of serum and urine decreased to 23 ng\/ml and 2.4 ng\/ml 4 months later, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This is the first report of a\n                      <jats:italic>de novo<\/jats:italic>\n                      NEPC presented with an elevated level of CEA, in which CEA was also detected in urine specimen post a prostatic massage. After a combination treatment of ADT for 3 months, levels of CEA in both serum and urine decreased sharply when tumor regressed radiologically. CEA might be a marker of screening and monitoring of NEPC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1508410","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:21:21Z","timestamp":1737678081000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["A case of de novo neuroendocrine prostate cancer presented with elevated level of serum CEA carrying BRCA2 mutation: case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Weizhe","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihati","family":"Rexiati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueli","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.04.006","article-title":"Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: A SEER database analysis","volume":"15","author":"Zaffuto","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: A multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.anndiagpath.2019.06.009","article-title":"Neuroendocrine tumors of genitourinary tract: Recent\u00a0advances","volume":"42","author":"Shehabeldin","year":"2019","journal-title":"Ann Diagn Pathol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10523.x","article-title":"Survival of patients with small cell carcinoma of the prostate during 1973-2003: a population-based study","volume":"109","author":"Deorah","year":"2012","journal-title":"BJU Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"15442","DOI":"10.1038\/s41598-018-33774-4","article-title":"Plasma androgen receptor and serum chromogranin A in advanced prostate cancer","volume":"8","author":"Conteduca","year":"2018","journal-title":"Sci Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/bies.20012","article-title":"Synaptophysin: leading actor or walk-on role in synaptic vesicle exocytosis","volume":"26","author":"Valtorta","year":"2004","journal-title":"Bioessays"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-013-9444-6","article-title":"Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis","volume":"32","author":"Beauchemin","year":"2013","journal-title":"Cancer Metastasis Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.605","article-title":"Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting","volume":"108","author":"Tiernan","year":"2013","journal-title":"Br J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3396","article-title":"Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer","volume":"27","author":"DeLucia","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41698-024-00599-6","article-title":"Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates","volume":"8","author":"Ajkunic","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-22-0491","article-title":"The identification of CELSR3 and other potential cell surface targets in neuroendocrine prostate cancer","volume":"3","author":"Van Emmenis","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2322203121","article-title":"Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies","volume":"121","author":"Zaidi","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1802354115","article-title":"Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer","volume":"115","author":"Lee","year":"2018","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.21","article-title":"Small cell carcinoma of the prostate","volume":"11","author":"Nadal","year":"2014","journal-title":"Nat Rev Urol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/bco2.v4.3","article-title":"Genomic alterations in neuroendocrine prostate cancer: A systematic review and meta-analysis","volume":"4","author":"Chen","year":"2023","journal-title":"BJUI Compass"},{"key":"B17","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1056\/NEJMc2023199","article-title":"Olaparib for metastatic castration-resistant prostate cancer. Reply","volume":"383","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/iju5.12543","article-title":"Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin","volume":"6","author":"Miyazawa","year":"2023","journal-title":"IJU Case Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1508410\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:21:23Z","timestamp":1737678083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1508410\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":18,"alternative-id":["10.3389\/fonc.2025.1508410"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1508410","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"article-number":"1508410"}}